Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-AbbVie Submits New Drug Application To FDA For Investigational ABBV-951 For Treatment Of Advanced Parkinson's Disease

BY Reuters
— 8:44 AM ET 05/20/2022

May 20 (Reuters) - Abbvie Inc (ABBV):

* ABBVIE SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INVESTIGATIONAL ABBV-951 (FOSCARBIDOPA/FOSLEVODOPA) FOR THE TREATMENT OF ADVANCED PARKINSON'S DISEASE

* ABBVIE INC (ABBV) - WILL CONTINUE TO PURSUE REGULATORY SUBMISSIONS FOR ABBV-951 ACROSS INTERNATIONAL MARKETS THROUGHOUT YEAR Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More ABBV News

AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease
PR Newswire - 8:15 AM ET 05/20/2022
AbbVie Whale Trades Spotted
Benzinga - 4:32 PM ET 05/19/2022
ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR Newswire - 2:00 PM ET 05/19/2022